Silo Pharma, Inc. (SILO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0200 |
| Open | 1.9800 |
| Bid | 1.9000 x 1000 |
| Ask | 2.1000 x 1200 |
| Day's Range | 1.9600 - 2.0600 |
| 52 Week Range | 0.1700 - 12.4500 |
| Volume | |
| Avg. Volume | 628,849 |
| Market Cap | 6.466M |
| Beta (5Y Monthly) | -0.84 |
| PE Ratio (TTM) | 66.45 |
| EPS (TTM) | 0.0310 |
| Earnings Date | Nov 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The study results evaluated the feasibility of using a rising dose design or maximum feasibility. In collaboration wi
- GlobeNewswire
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application for the use of its central nervous system (CNS) homing peptides to treat Alzheimer's disease and th
- GlobeNewswire
Silo Pharma Announces Expansion of Intellectual Property Portfolio
Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective DisordersENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against
